Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Former CDER official joins Greenleaf Health, biosimilars experience in tow

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Who's going to run Celgene when Hugin hangs it up?

With Celgene CEO Bob Hugin working through his 15th year at the company, an internal race to spot his eventual successor appears to be in progress, and the Big Biotech's latest round of promotions provides some clues to its future leadership.

Forest CEO Saunders to lead combined company after Actavis buyout

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Prepping for $25B merger, Actavis taps Forest CEO Saunders to lead combined company

When Actavis CEO Paul Bisaro announced his big buyout of Forest Laboratories, he sketched a picture of a brand-plus-generic powerhouse with lower costs and bigger revenue prospects. Now, it will be Forest CEO Brent Saunders who colors in those lines as chief executive of the merged company.

Bristol-Myers' senior VP of global development retires

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Endo appoints former Bausch + Lomb exec to head corporate strategy

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Actavis global R&D president departs to helm Impax Labs

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Former Creighton professor named chief medical officer at 23andMe

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Chimerix CEO Moch steps down after compassionate-use controversy

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Soon after media storm fades, Chimerix CEO Moch is out the door

Just weeks after enduring a storm of controversy triggered by his initial refusal to provide a potent but experimental antiviral to a dying child under a compassionate use program, Chimerix CEO Ken Moch is out. The company announced that Moch had resigned--completely unexpectedly--to "pursue other interests" as the board introduced a new CEO to run the company.